Cx601

February 17, 2015February 17, 2015

TiGenix And Lonza Partner For Complex Perianal Fistulas In Crohn’s Disease Treatment

Crohn's Disease, News

TiGenix, an advanced biotechnological company committed to developing and marketing new therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) for autoimmune and inflammatory diseases, together with Lonza, a leading and global company of ... Read more

November 13, 2014November 13, 2014

TiGenix Completes Phase 3 Cx601 Trial Enrollment in Europe

News

Leading European cell therapy company TiGenix NV has just announced the successful full enrollment of patients for a Phase III clinical trial of Cx601, the company’s pipeline treatment for complex perianal fistulas ... Read more

September 10, 2014September 10, 2014

European Medicines Agency Gives Positive Opinion on TiGenix’s Pediatric Investigation Plan For CD Perianal Fistulas Treatment

Crohn's Disease, News

Biopharmaceutical company TiGenix NV, which is currently developing and commercializing novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells (eASC’s) for inflammatory and autoimmune diseases, announced that it received ... Read more